Clinical Study Results
Research Sponsor: Acerta Pharma BV
Treatment Studied: Ceralasertib and Acalabrutinib
Study Purpose: This study was done to learn how Ceralasertib works and about its safety when taken by itself and with Acalabrutinib in participants with chronic lymphocytic leukemia.
Protocol Number: ACE-CL-110, also known as D5330C00008

Thank you for taking part in the clinical study for the study drugs Acalabrutinib and Ceralasertib. Ceralasertib is also known as AZD6738.
Acerta Pharma BV, a member of the AstraZeneca Group of companies, sponsored this study and believes it is important to share the results. An independent non-profit organization called CISCRP helped prepare this summary of the study results for you.
If you participated in the study and have questions about the results, please speak with the study doctor or staff at your study site.